Tryptamine Therapeutics (Tryp) has announced the completion of subject dosing in a Phase Ib clinical trial of TRP-8803, for ...
The Phase I trial of the combination therapy saw a an approximate 66% rate of near-complete remission in its cohort of breast ...
Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback